Tarsus Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
On June 1, 2026, Elizabeth Yeu-Lin, our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement (the “Yeu-Lin Plan”) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The Yeu-Lin Plan provides for the potential sale of up to 9,506 shares of common stock held by Ms. Yeu-Lin between September 1, 2026 and August 31, 2027. Also on June 1, 2026, thespouse of Ms. Yeu-Lin adopted a Rule 10b5-1 trading arrangement (the “Spousal Plan”) covering shares of the Company's common stock in which Ms. Yeu-Lin has an indirect pecuniary interest reportable under Section 16 of the Exchange Act. The Spousal Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and provides for the potential sale of up to 6,360 shares of the Company's common stock, between September 1, 2026 and September 1, 2027.
During the quarter ended June 30, 2026, none of our other officers or directors, as defined in Rule 16a-1(f), informed us of anadoption ortermination of a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement, each as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.